Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma

Molecular Cancer Therapeutics

Volumn 12, Issue 6, 2013, Pages 844-852

  Nuvoli, Barbara ^a   Galati, Rossella ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANASTROZOLE; AROMATASE; BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DEPSIPEPTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EXEMESTANE; FULVESTRANT; GEFITINIB; PEMETREXED; PROTEIN P21; PROTEIN P27; PROTEIN P53; ROFECOXIB;

ADVANCED CANCER; BREAST CANCER; CARCINOGENESIS; CELL PROLIFERATION; DOWN REGULATION; DRUG EFFICACY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LUNG NON SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

AROMATASE; ASBESTOS; CYCLOOXYGENASE 2; HUMANS; INFLAMMATION; LUNG NEOPLASMS; MESOTHELIOMA; MOLECULAR TARGETED THERAPY; PLEURAL NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84879288077     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1103     Document Type: Review

References (78)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:3-603.
2. Mossman BT, Kamp DW, Weitzman SA. Mechanisms of carcinogen-esis and clinical features of asbestos-associated cancers. Cancer Invest 1996;14:3-80.
3. Carbone M, Pass HI, Miele L, Bocchetta M. New developments about the association of SV40 with human mesothelioma. Oncogene 2003;22:5173-80.
4. Rivera Z, Strianese O, Bertino P, Yang H, Pass H, Carbone M. The relationship between simian virus 40 and mesothelioma. Curr Opin Pulm Med 2008;14:316-21.
5. Kamp DW, Weitzman SA. The molecular basis of asbestos induced lung injury. Thorax 1999;54:3-52
6. Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med 1998;157:3-80.
7. Burt BM, Bader A, Winter D, Rodig SJ, Bueno R, Sugarbaker DJ. Expression of interleukin-4 receptor alpha by human pleura mesothe-lioma is associated with poor survival and promotion of tumour inflammation. Clin Cancer Res 2012;18:3-77.
8. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010;10:181-93.
9. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 2008;99:3-6.
10. Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol 1999;189: 3-8.
11. Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, et al. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer 2012;77:3-71.
12. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-93.
13. Oshima H, Popivanova BK, Oguma K, Kong D, Ishikawa TO, Oshima M. Activation of epidermal growth factor receptor signalling by the prostaglandin E(2) receptor EP4 pathway during gastric tumourigen-esis. Cancer Sci 2011;102:3-9.
14. Lippman SM, Gibson N, Subbaramaiah K, Dannenberg AJ. Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clin Cancer Res 2005;11:6097-9.
15. Shukla A, Barrett TF, Macpherson MB, Hillegass JM, Fukagawa NK, Swain WA, et al. An ERK2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury. Am J Respir Cell Mol Biol 2011;45:906-14.
16. Gutkind JS. The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. J Biol Chem 1998;273:1839-42.
17. Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohad-wala M, et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signalling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 2005;65:6275-81.
18. Chan E, Lafleur B, Rothenberg ML, Merchant N, Lockhart AC, Trivedi B, et al. Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer. Am J Clin Oncol 2011;34:3-6
19. Stoppoloni D, Canino C, Cardillo I, Verdina A, Baldi A, Sacchi A, et al. Synergistic effect of gefitinib and rofecoxib in mesothelioma cells. Mol Cancer 2010;9:27.
20. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996;137:3-42.
21. Richards JA, Petrel TA, Brueggemeier RW. Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J Steroid Biochem Mol Biol 2002;80:3-12.
22. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) 2011;4:3-9.
23. Slattery ML, Lundgreen A, Herrick JS, Kadlubar S, Caan BJ, Potter JD, et al. Variation in the CYP19A1 gene and risk of colon and rectal cancer. Cancer Causes Control 2011;22:3-63.
24. Bulun SE, Monsavais D, Pavone ME, Dyson M, Xue Q, Attar E, et al. Role of oestrogen receptor-β in endometriosis. Semin Reprod Med 2012;30:3-45.
25. Stoppoloni D, Salvatori L, Biroccio A, D'Angelo C, Muti P, Verdina A, et al. Aromatase inhibitor exemestane has antiproliferative effects on human mesothelioma cells. J Thorac Oncol 2011;6:3-91
26. Harris RE. Cyclooxygenase-2 (COX-2) and the inflammogenesis of cancer. Subcell Biochem 2007;42:3-126.
27. Cardillo I, Spugnini EP, Verdina A, Galati R, Citro G, Baldi A. Cox and mesothelioma, an overview. Histol Histopathol 2005;20:3-74
28. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcino-genesis 2009;30:3-86.
29. Prescott SM, Fitzpatrick FA. Cyclooxygenase and carcinogenesis. Biochim Biophys Acta 2000;1470:M69-78.
30. Edwards JG, Faux SP, Plummer SM, Abrams KR, Walker RA, Waller DA, et al. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res 2002;8:1857-62.
31. Mineo TC, Ambrogi V, Cufari ME, Pompeo E. May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleura mesothelioma? Eur J Cardiothorac Surg 2010;38:3-52.
32. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 30-untranslated region. J Biol Chem 2000;275:3-7.
33. Dixon DA, Tolley ND, King PH, Nabors LB, McIntyre TM, Zimmerman GA, et al. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 2001;108:3-65.
34. Stoppoloni D, Cardillo I, Verdina A, Vincenzi B, Menegozzo S, Santini M, et al. Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: association with cyclooxygen-ase-2 and prognosis. Cancer 2008;113:3-9.
35. Zahner G, Wolf G, Ayoub M, Reinking R, Panzer U, Shankland SJ, et al. Cyclooxygenase-2 overexpression inhibits platelet-derived growth factor-induced mesangial cell proliferation through induction of the tumour suppressor gene p53 and the cyclin-dependent kinase inhibitors p21waf-1/cip-1 and p27kip-1. J Biol Chem 2002; 277:3-71.
36. Bongiovanni M, Cassoni P, De Giuli P, Viberti L, Cappia S, Ivaldi C, et al. p27kip1 immunoreactivity correlates with long-term survival in pleural malignant mesothelioma. Cancer 2001;92:3-50.
37. Baldi A, Groeger AM, Esposito V, Cassandro R, Tonini G, Battista T, et al. Expression of p21 in SV40 large T antigen positive human pleural mesothelioma: relationship with survival. Thorax 2002;57:3-6.
38. Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG, et al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer 2010;10:464.
39. O'Kane SL, Eagle GL, Greenman J, Lind MJ, Cawkwell L. COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer 2010;67:160-5.
40. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004;59:21-6.
41. Oda K, Matsuoka Y, Funahashi A. A comprehensive pathway map of epidermal growth factor receptor signalling. Mol Syst Biol 2005;1:1.
42. Zanella CL, Posada J, Tritton TR, Mossman BT. Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res 1996;56:5334-8.
43. Pache JC, Janssen YM, Walsh ES, Quinlan TR, Zanella CL, Low RB, et al. Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers. Am J Pathol 1998;152:333-40.
44. Cai YC, Roggli V, Mark E, Cagle PT, Fraire AE. Transforming growth factor alpha and epidermal growth factor receptor in reactive and malignant mesothelial proliferations. Arch Pathol Lab Med 2004;128: 68-70.
45. Jänne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of epidermal growth factor receptor signalling in malignant pleural mesothelioma. Cancer Res 2002;62:5242-7.
46. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37:S9-S15.
47. Dazzi H, Hasleton PS, Thatcher N, Wilkes S, Swindell R, Chatterjee AK. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 1990;61:924-26.
48. Destro A, Ceresoli GL, Falleni M. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 2006; 51:207-15.
49. Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer R, Watson D, et al. Cancer and Leukemia Group B (CALGB 30101). Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005;11:2300-4.
50. Ramael M, Segers K, Buysse C, Van den Bossche J, Van Marck E. Immunohistochemical distribution patterns of epidermal growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium. Virchows Arch A Pathol Anat Histopathol 1991;419: 171-5.
51. Trupiano JK, Geisinger KR, Willingham MC, Manders P, Zbieranski N, Case D, et al. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 2004;17:3-81.
52. Okuda K, Sasaki H, Kawano O, Yukiue H, Yokoyama T, Yano M, et al. Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. J Cancer Res Clin Oncol 2008;134:1105-11.
53. Rena O, Boldorini LR, Gaudino E, Casadio C. Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: Prognostic correlations. J Surg Oncol 2011;104:701-5.
54. Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007;25:3-13.
55. Foster JM, Gatalica Z, Lilleberg S, Haynatzki G, Loggie BW. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma. Ann Surg Oncol 2009;16:3-8
56. Foster JM, Radhakrishna U, Govindarajan V, Carreau JH, Gatalica Z, Sharma P, et al. Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. World J Surg Oncol 2010;8:88.
57. Ou WB, Hubert C, Corson JM, Bueno R, Flynn DL, Sugarbaker DJ, et al. Targeted inhibition of multiple receptor tyrosine kinases in mesothe-lioma. Neoplasia 2011;13:3-22.
58. Pinton G, Thomas W, Bellini P, Manente AG, Favoni RE, Harvey BJ, et al. Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib. PLoS ONE 2010;5:e14110.
59. Bulun SE, Takayama K, Suzuki T, Sasano H, Yilmaz B, Sebastian S. Organization of the human aromatase p450 (CYP19A1) gene. Semin Reprod Med 2004;22:3-9.
60. Patrone C, Cassel TN, Pettersson K, Piao YS, Cheng G, Ciana P, et al. Regulation of postnatal lung development and homeostasis by oestrogen receptor beta. Mol Cell Biol 2003;23:8542-52
61. Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, et al. Human non-small cell lung tumours and cells derived from normal lung express both oestrogen receptor α and β and show biological responses to oestrogen. Cancer Res 2002;62:2141-50.
62. Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M. Oestrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 2005;70: 372-81.
63. Chen GG, Zeng Q, Tse GM. Oestrogenandits receptors in cancer. Med Res Rev 2008;28:954-74.
64. Simoncini T, Genazzani AR. Non-genomic actions of sex steroid hormones. Eur J Endocrinol 2003;148:281-92.
65. Simoncini T, Mannella P, Fornari L, Caruso A, Varone G, Genazzani AR. Genomic and non-genomic effects of oestrogens on endothelial cells. Steroids 2004;69:537-542.
66. Levin ER. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 2003; 309-17.
67. Migliaccio A, Di Domenico M, Castoria G, Nanayakkara M, Lombardi M, De Falco A, et al. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action. Cancer Res 2005;65:10585-93.
68. Migliaccio A, Castoria G, Di Domenico M, Ciociola A, Lombardi M, De Falco A, et al. Crosstalk between EGFR and extranuclear steroid receptors. Ann N Y Acad Sci 2006;1089:194-200.
69. Filardo EJ, Quinn JA, Frackelton AR Jr, Bland KI. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 2002;16: 70-84
70. Reed MJ, Coldham NG, Patel SR, Ghilchik MW, James VH. Interleukin-1 and interleukin-6 in breast cyst fluid: their role in regulating aromatase activity in breast cancer cells. J Endocrinol 1992;132:R5-R8.
71. Orengo AM, Spoletini L, Procopio A, et al. Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. Eur Respir J 1999;13:3-34
72. Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, et al. Oestrogen receptor β impacts on prognosis of human malignant mesothelioma. Cancer Res 2009;69:4598-604.
73. Metintas S, Metintas M, Ucgun I, Oner U. Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. Chest 2002;122:3-9.
74. Carbone M, Emri S, Dogan AU, Steele I, Tuncer M, Pass HI, et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer 2007;7:3-54.
75. Hansen J, De Klerk NH, Musk AW, Hobbs MS. Environmentalexposure to Crocidolite and mesothelioma, exposure response relationships. Am J Respir Crit Care Med 1998;157:69-75.
76. Chua TC, Yao P, Akther J, Morris DL. Differential expression of Ki-67 and sex steroid hormone receptors between genders in peritoneal mesothelioma. Pathol Oncol Res 2009;15:3-8.
77. Travis WD, Colby TV, Corrin B. Histological typing of lung and pleural tumours. 3rd ed. Berlin, Germany: Springer; 1999.
78. Neragi-Miandoab S, Richards WG, Sugarbaker DJ. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma. Int J Surg 2008;6:293-97.